






ORIGINAL RESEARCH

Genetically Proxied Inhibition of Coagulation Factors and Risk of Cardiovascular Disease: A Mendelian Randomization Study

Shuai Yuan , MB, MSc; Stephen Burgess, PhD; Mike Laffan, PhD; Amy M. Mason , PhD; Martin Dichgans , PhD; Dipender Gill , PhD*; Susanna C. Larsson , PhD*

BACKGROUND: We conducted Mendelian randomization analyses investigating the linear associations of genetically proxied inhibition of different coagulation factors with risk of common cardiovascular diseases.

METHODS AND RESULTS: Genetic instruments proxying coagulation factor inhibition were identified from genome-wide association studies for activated partial thromboplastin time and prothrombin time in BioBank Japan (up to 58 110 participants). Instruments were identified for 9 coagulation factors (fibrinogen alpha, beta, and gamma chain; and factors II, V, VII, X, XI, and XII). Age- and sex-adjusted estimates for associations of the instruments with the outcomes were derived from UK Biobank and the FinnGen, CARDIoGRAMplusC4D (Coronary Artery Disease Genome-wide Replication and Meta-analysis), and MEGASTROKE consortia with numbers of incident and prevalent cases of 820 to 60 810. Genetically proxied inhibition of fibrinogen alpha, beta, and gamma chain, factor II, and factor XI were associated with reduced risk of venous thromboembolism ($P < 0.001$). With the exception of fibrinogen beta and factor II, inhibition of these factors was also associated with reduced risk of any ischemic stroke and cardioembolic stroke ($P \leq 0.002$). Genetically proxied inhibition of fibrinogen beta and gamma were associated with reduced large-artery stroke risk ($P = 0.001$). There were suggestive protective associations of genetically proxied inhibition of factors V, VII, and X with ischemic stroke ($P < 0.05$), and suggestive adverse associations of genetically proxied inhibition of factors II and XII with subarachnoid hemorrhage.

CONCLUSIONS: This study supports targeting fibrinogen and factor XI for reducing venous thromboembolism and ischemic stroke risk, and showed suggestive evidence that inhibition of factors V, VII, and X might reduce ischemic stroke risk.

Key Words: cardiovascular disease ■ coagulation ■ Mendelian randomization analysis ■ stroke ■ venous thromboembolism

By inhibiting components of the coagulation cascade, current anticoagulant therapies have proven effective for the prevention and treatment of venous thromboembolism (VTE).^{1,2} Anticoagulant therapies also reduce risk of other cardiovascular diseases (CVDs) via effects on thrombosis,^{3–6} with the adverse consequence of increasing risk of bleeding complications.⁴ However, given large differences in the role of individual coagulation factors in CVD subtypes, the efficacy and safety of anticoagulants targeting different coagulation factors remains largely unknown.⁷

Recent meta-analyses of randomized clinical trials aimed to compare the health benefits, adverse effects, and cost-effectiveness across different anticoagulant drugs,^{6,8} thereby informing on optimized anticoagulant treatment strategies. However, with the exception of approved antithrombotic agents such as vitamin K antagonists and factor IIa and factor Xa inhibitors, these questions could not be satisfactorily addressed because of insufficient availability of clinical trial data.⁸

By employing genetic variants as instrumental variables for coagulation factors in a Mendelian randomization

Correspondence to: Susanna C. Larsson, PhD, Unit of Cardiovascular and Nutritional Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Nobels väg 13, Stockholm, 17177, Sweden. Email: susanna.larsson@ki.se

Supplementary Material for this article is available at <https://www.ahajournals.org/doi/suppl/10.1161/JAHA.120.019644>

*D. Gill and S. Larsson contributed equally and are co-last authors.

For Sources of Funding and Disclosures, see page 11.

© 2021 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

JAHA is available at: www.ahajournals.org/journal/jaha

CLINICAL PERSPECTIVE

What Is New?

- Genetically proxied inhibition of fibrinogen alpha, beta, and gamma chain and factors II and XI were associated with reduced risk of venous thromboembolism.
- With the exception of fibrinogen beta and factor II, inhibition of these factors was also associated with reduced risk of any ischemic stroke and cardioembolic stroke.
- Genetically proxied inhibition of fibrinogen alpha and gamma were associated with reduced large-artery stroke risk.

What Are the Clinical Implications?

- The present Mendelian randomization study supports the efficacy of anticoagulants targeting fibrinogen, factor II, and factor XI in treating venous thromboembolism and revealed potential applications of inhibition of fibrinogen and factor XI for lowering risk of ischemic stroke, particularly cardioembolic stroke.
- Increased bleeding risk accompanied by these anticoagulants needs to be carefully assessed in further studies.

Nonstandard Abbreviations and Acronyms

aPTT	activated partial thromboplastin time
MR	Mendelian randomization

(MR) framework, the clinical effects of inhibition of different pathways of the coagulation cascade can be assessed using observational data. This approach can strengthen the causal inference in an exposure-outcome association by reducing residual confounding and reverse causality.^{9,10} Because genetic variants are randomly allocated at conception, values of the exposure predicted by genetic variants are generally not correlated with other environmental factors, thus minimizing confounding. This process resembles the random assignment of participants to treatment and control groups in a randomized controlled trial. In addition, alleles of genetic variants are fixed at birth and cannot be modified by the onset or progression of the disease, and thus, the MR design also diminishes risk of reverse causality.

Previous and ongoing clinical trials have aimed to assess effects of different anticoagulants on atherosclerotic, thrombotic, and hemorrhagic CVDs. Anticoagulant drugs targeting a coagulation factor have been approved or are under investigation (Table 1). Clinical trials of oral anticoagulants often use intracranial hemorrhage, which includes intracerebral

hemorrhage, subarachnoid hemorrhage, and epidural and subdural bleeds, as a measure for bleeding complications. Given that the latter 2 of these bleeding complications are rare, intracerebral and subarachnoid hemorrhage were used to evaluate bleeding complications in the present investigation.

Here, we conducted a 2-sample MR study to comprehensively assess the potential effect of inhibiting 9 coagulation factors on risk of 9 thrombosis-related CVDs, including VTE, ischemic stroke and its etiologic subtypes, coronary artery disease, peripheral arterial disease, and intracerebral and subarachnoid hemorrhage. Secondary outcomes included heart failure, atrial fibrillation, aortic valve stenosis, and abdominal aortic aneurysm.

METHODS

Study Design

For coagulation factors involved in cell-based coagulation cascade (Figure 1),¹¹ we identified genetic proxies as single-nucleotide polymorphisms (SNPs) associated with activated partial thromboplastin time (aPTT) or prothrombin time (PT) and located within the gene region of the corresponding factor. We only used *cis*-variants (variants in the relevant coding gene region) as genetic proxies. To explore whether the effects are target specific, we also selected SNPs associated with aPTT or PT and examined their associations with outcomes in supplementary analyses. Summary-level data for aPTT and PT were obtained from BioBank Japan on 37 767 and 58 110 individuals, respectively.¹² Genetic instruments were identified for the 9 coagulation factors, aPTT, and PT listed in Table 1 (there were no suitable SNPs for factor VIII and IX in their coding gene region). Outcome data were obtained from UK Biobank¹³ and the FinnGen,¹⁴ MEGASTROKE,¹⁵ and CARDIoGRAMplusC4D (Coronary Artery Disease Genome-wide Replication and Meta-analysis)¹⁶ consortia. All studies had obtained ethical approval, and participants had given informed consent.

Genetic Instrument Construction

We constructed a genetic instrument consisting of SNPs associated with aPTT or PT at $P < 5 \times 10^{-8}$. For coagulation factors in the common pathway (ie, factors II, V, and X), the weights of genetic instruments from the association with PT were applied because no SNP associated with aPTT was identified at $P < 5 \times 10^{-8}$. Independent SNPs ($r^2 < 0.01$ and clumping window $> 10\ 000$) within the coding gene region of the corresponding coagulation factor were used as instrumental variables. Linkage disequilibrium r^2 and clumping window were estimated based on 1000 Genomes linkage disequilibrium reference panel (with only European population) and were obtained using the *ld_matrix*

Table 1. Coagulation Factors Included in This Mendelian Randomization Study and Information on Genetic Instrument Selection

Factor	Name	Related Measures	Gene	Chromosome	Position Start*	Position End*	SNPs	Previous MR Evidence	Approved Anticoagulants
I	Fibrinogen alpha chain	aPTT & PT	FGA	4	155504280	155511897	1	Yes	No
	Fibrinogen beta chain	aPTT & PT	FGB	4	155484132	155493915	1		No
	Fibrinogen gamma chain	aPTT & PT	FGG	4	155525286	155533902	1		No
II	Prothrombin	aPTT & PT	F2	11	46740743	46761056	1	No	Dabigatran, heparin, and enoxaparin
V	Proaccelerin or labile factor	aPTT & PT	F5	1	169481192	169555769	3	No	No
VII	Proconvertin or stable factor	PT	F7	13	113760102	113774995	1	Yes	No
X	Stuart-Prower factor	aPTT & PT	F10	13	113777113	113803843	1	Yes	Warfarin, apixaban, enoxaparin, rivaroxaban, dalteparin, nadroparin calcium, fondaparinux sodium
XI	Plasma thromboplastin antecedent	aPTT	F11	4	187187099	187210835	1	Yes	No
XII	Hageman factor	aPTT	F12	5	176829139	176836577	1	No	No
...	aPPT	aPPT	19	No	...
...	PT	PT	15	No	...

aPTT indicates activated partial thromboplastin time; MR, Mendelian randomization; PT, prothrombin time; and SNP, single-nucleotide polymorphism.

*Based on genome build GRCh37/hg19.




Figure 1. Coagulation factors involved in cell-based coagulation cascade. Activated partial thromboplastin time is used to evaluate the coagulation factors XII, XI, IX, VIII, X, V, II, and I. Prothrombin time evaluate the coagulation factors VII, X, V, II, and I. TF, tissue factor; VWF, von Willebrand factor.

Downloaded from <http://ahajournals.org> by on April 16, 2021

command in the TwoSampleMR package.¹⁷ SNPs in linkage disequilibrium within a particular window were pruned, and the SNP with the lowest *P* value was retained. The SNPs used as instrumental variables are shown in Table S1.

Outcome Sources

The UK Biobank study¹³ was used to estimate genetic association with 10 CVDs, including the 6 major outcomes (VTE, ischemic stroke, coronary artery disease, peripheral arterial disease, and intracerebral and subarachnoid hemorrhage), among 367 643 adults (37–73 years of

age at baseline) of European ancestry after exclusion of relatedness of third degree or higher, low genotype call rate (≥ 3 SDs from the mean), and excess heterozygosity. The participants were followed until March 31, 2017, or the date of death (recorded until February 14, 2018) with a median follow-up of 8.0 years. CVD diagnosis was based on electronic health records, hospital procedure codes, and self-reported information validated by interview with a nurse (Table S2). Clinical outcomes were not adjudicated by independent committee by predefined criteria. Beta coefficients and standard errors of the genetic associations with CVD were calculated using

logistic regression with adjustment for age, sex, and 10 genetic principal components.

Publicly available summary-level data were obtained for VTE and hemorrhagic stroke from the FinnGen consortium,¹⁴ for ischemic stroke from the MEGASTROKE consortium,¹⁵ and for coronary artery disease from the CARDIoGRAMplusC4D consortium.¹⁶ The FinnGen consortium R4 includes 6913 VTE cases, 1224 intracerebral hemorrhage cases, 1019 subarachnoid hemorrhage cases, and >163 500 noncases of Finnish descent. Association tests were adjusted for age, sex, 10 genetic principal components, and genotyping batch. The MEGASTROKE consortium includes 34 271 ischemic stroke cases and 404 630 noncases of European ancestry, and 4373 large-artery stroke cases, 5386 small-vessel stroke cases, and 7193 cardioembolic stroke cases. The MEGASTROKE consortium had some participant overlap with the FinnGen consortium, and therefore FinnGen was not used for analyses of ischemic stroke. The CARDIoGRAMplusC4D consortium involves 60 801 individuals with coronary heart disease and 123 504 noncases (77% of participants were of European ancestry). All SNPs used as instrumental variables for the coagulation factors were available in all outcome data sources. Diagnostic information for outcomes in FinnGen and consortia is presented in Tables S3 and S4.

Statistical Analysis

The fixed-effects inverse-variance weighted method was used to assess the associations of coagulation factors with 10 CVDs (5 primary and 5 secondary outcomes) in the main analysis.¹⁸ Estimates were combined from different data sources using the fixed-effects meta-analysis method. The invariance weighted method with random effects was used to estimate the association of genetically predicted aPTT and PT with CVDs. All odds ratios and 95% CIs of the CVD outcomes were scaled to a 1-second increase in aPTT and PT. The Bonferroni correction method was used to account for multiple testing. We deemed associations with $P < 0.001$ (where $P = 0.05/54$ [6 primary outcomes and 9 coagulation factors]) as strong evidence of causal associations. Associations with $P < 0.05$ but > 0.001 were treated as suggestive evidence of associations. Analyses were performed using the *mrrobust* package¹⁹ in Stata/SE 15.0 (StataCorp, College Station, TX) and the MendelianRandomization²⁰ and TwoSampleMR¹⁷ packages in R software 3.6.0 (R Foundation for Statistical Computing, Vienna, Austria).

Pleiotropy Assessment

To detect possible pleiotropic effects of used SNPs for coagulation factors, we searched used genetic instruments in PhenoScanner V2 (a database of

human genotype-phenotype associations)²¹ to obtain associated phenotypes at the genome-wide significance level. Pleiotropy could not be explored statistically using MR sensitivity analyses because of a limited number of SNPs for each coagulation factor.

Data Availability

The data that support the findings of this study are available from the corresponding author upon reasonable request.

RESULTS

Associations of coagulation factors with VTE and ischemic stroke and its subtypes are displayed in Figures 2 through 4. Other associations are displayed in Table 2. Genetically predicted prolonged aPTT was suggestively associated with heart failure, atrial fibrillation, and ischemic stroke, but not associated with other outcomes (Figure S1). There was no association between genetically predicted PT and cardiovascular outcomes (Figure S1).

Genetically proxied inhibition of the coagulation cascade via fibrinogen alpha, beta, and gamma chain and factors II and XI was significantly associated with reduced risk of VTE in the meta-analysis of data from UK Biobank and FinnGen ($P < 0.001$). The odds ratios scaled to a 1-second increase in aPTT or PT were 0.04 (95% CI, 0.03–0.06) for fibrinogen alpha chain, 0.51 (95% CI, 0.34–0.77) for fibrinogen beta chain, 0.04 (95% CI, 0.03–0.06) for fibrinogen gamma chain, 0.16 (95% CI, 0.08–0.32) for factor II, and 0.15 (95% CI, 0.12–0.19) for factor XI. Genetically proxied inhibition of fibrinogen alpha and gamma chain and factor XI was also significantly associated with lower risk of ischemic stroke in the meta-analysis of UK Biobank and MEGASTROKE data, and corresponding odds ratios were 0.36 (95% CI, 0.25–0.52), 0.37 (95% CI, 0.26–0.53), and 0.72 (95% CI, 0.58–0.88), respectively. With regard to subtypes of ischemic stroke, fibrinogen alpha and gamma and factor XI were associated with cardioembolic stroke ($P < 0.001$). Fibrinogen alpha and gamma were further associated with large-artery stroke ($P < 0.001$). There were suggestive protective associations ($P < 0.05$) of genetically proxied inhibition of fibrinogen beta and factors V, VII, and X with risk of ischemic stroke, and suggestive adverse effects of genetically proxied inhibition of factors II and XII on subarachnoid hemorrhage.

Phenotypes associated with variants used to proxy coagulation factor inhibition at the genome-wide significance level are displayed in Table S5. As expected, most variants were associated with




Figure 2. Genetically proxied inhibition of coagulation factors and venous thromboembolism (15 602 cases in UK Biobank and 6913 cases in FinnGen) in the main analysis.

FGA indicates fibrinogen alpha chain; FGB, fibrinogen beta chain; FGG, fibrinogen gamma chain; IS, ischemic stroke; OR, odds ratio; UKBB, UK Biobank; and VTE, venous thromboembolism. Combined estimates were estimated using fixed-effect meta-analysis method.

thrombosis-related phenotypes, such as self-reported deep vein thrombosis, pulmonary embolism, and phlebitis and thrombophlebitis, in genome-wide association studies of European individuals. In addition, we found the effect allele of rs2059503 (inhibition of fibrinogen beta chain) to be associated with higher levels of aspartate transaminase, a marker of liver function. The effect allele of rs2070850 (inhibition of factor II) was associated

with lower levels of high-density lipoprotein cholesterol, bone mineral density and height, and lower liability to self-reported hypertension. Rs2282686 (inhibition of factor II) was also associated with bone mineral density. The effect allele of rs9332653 (inhibition of factor V) was associated with lower blood protein levels, and the effect allele of 2 SNPs for factor XII inhibition was associated with increased height.




Figure 3. Genetically proxied inhibition of coagulation factors and ischemic stroke (4602 cases in UKBB and 34 272 cases in MEGASTROKE) in the main analysis.

FGA indicates fibrinogen alpha chain; FGB, fibrinogen beta chain; FGG, fibrinogen gamma chain; IS, ischemic stroke; OR, odds ratio; and UKBB, UK Biobank. Combined estimates were estimated using fixed-effect meta-analysis method.

DISCUSSION

This MR study strengthens the evidence of causal associations of fibrinogen and factors II and XI with VTE. More importantly, we observed robust evidence that inhibition of fibrinogen and factor XI reduces the risk of ischemic stroke, particularly cardioembolic stroke. Additionally, we found suggestive evidence that inhibition of factors V, VII, and X might reduce the risk of

ischemic stroke. These findings imply possible benefits of anticoagulant therapies targeting those coagulation factors in the prevention of ischemic stroke. We did not detect any significant associations of coagulation factors with other CVD outcomes, in contrast to evidence from clinical trials on factor Xa²² and thrombin inhibitors.²³ A possible increased risk of hemorrhagic stroke could not be excluded for other anticoagulants and requires further study. Inhibition of factor VII, for




Figure 4. Genetically proxied inhibition of coagulation factors and subtypes of ischemic stroke (4373 large artery stroke, 5386 small vessel stroke and 7193 cardioembolic stroke cases from MEGASTROKE) in the main analysis.

FGA indicates fibrinogen alpha chain; FGB, fibrinogen beta chain; FGG, fibrinogen gamma chain; and OR, odds ratio. Combined estimates were estimated using fixed-effect meta-analysis method.

example, may cause increased risk of severe intracranial hemorrhage.²⁴

Overall, our findings were consistent with previous studies on the role of different coagulation factors in venous thrombosis.^{25–27} Identified protective effects of coagulant factor inhibition on ischemic stroke were also in agreement with meta-analysis of clinical trials,²⁸ and recent MR studies on factor XI.^{29–31} Notably, the present investigation went

further to assess the effects of 9 coagulation factors on thrombosis and other CVD outcomes. Possible adverse effects of different anticoagulants should be considered further. As the CIs for the association with hemorrhagic stroke would still be compatible with clinically relevant risk increase, more evidence is needed to accurately estimate any potential impact of different coagulation factors on bleeding risk. This could be achieved by MR studies with greater

Table 2. Genetically Proxied Inhibition of Coagulation Factors and Other Cardiovascular Outcomes

Data source	FGA			FGB			FGG			FII			FV		
	OR	95% CI	P Value	OR	95% CI	P Value	OR	95% CI	P Value	OR	95% CI	P Value	OR	95% CI	P Value
Cardiovascular Disease															
UKBB	1.09	0.76–1.57	0.65	0.97	0.68–1.39	0.86	0.93	0.66–1.32	0.69	1.07	0.57–2.00	0.84	0.99	0.84–1.17	0.94
CARDIoGRAMplusC4D	0.86	0.60–1.25	0.43	1.08	0.75–1.55	0.68	0.84	0.59–1.19	0.33	0.91	0.49–1.69	0.77	0.88	0.76–1.02	0.10
UKBB	1.43	0.70–2.94	0.33	0.76	0.37–1.54	0.44	1.34	0.67–2.67	0.41	1.06	0.31–3.66	0.92	0.89	0.64–1.23	0.47
UKBB	0.98	0.62–1.55	0.93	1.22	0.77–1.93	0.39	0.91	0.59–1.42	0.69	0.62	0.28–1.36	0.23	0.79	0.64–0.98	0.03
UKBB	0.53	0.16–1.80	0.31	1.53	0.46–5.07	0.49	0.48	0.15–1.54	0.22	0.72	0.09–5.96	0.76	0.96	0.55–1.69	0.89
UKBB	1.60	0.27–9.33	0.60	1.23	0.22–6.94	0.81	0.98	0.18–5.30	0.98	0.64	0.03–13.07	0.77	1.54	0.7–3.39	0.28
UKBB	2.80	0.46–16.93	0.26	2.85	0.51–15.86	0.23	2.88	0.51–16.30	0.23	0.23	0.01–4.71	0.34	0.81	0.36–1.83	0.61
FinnGen	1.94	0.40–9.4	0.41	0.26	0.05–1.39	0.12	1.50	0.33–6.76	0.60	0.37	0.03–4.81	0.45	1.16	0.62–2.15	0.65
UKBB	1.89	0.32–11.13	0.48	1.75	0.31–9.74	0.52	2.56	0.46–14.18	0.28	43.9	1.78–1080	0.02	2.13	0.99–4.58	0.05
FinnGen	0.43	0.08–2.39	0.33	4.96	0.81–30.25	0.08	0.32	0.06–1.63	0.17	0.32	0.02–5.15	0.42	1.41	0.72–2.78	0.32
UKBB	0.78	0.29–2.11	0.63	1.12	0.42–3.00	0.82	0.74	0.29–1.93	0.54	1.68	0.30–9.45	0.56	0.95	0.61–1.48	0.82
	FVII			FX			FXI			FXII					
Cardiovascular disease	OR	95% CI	P Value	OR	95% CI	P Value	OR	95% CI	P Value	OR	95% CI	P Value	OR	95% CI	P Value
UKBB	0.97	0.91–1.03	0.31	0.95	0.88–1.03	0.19	1.06	0.88–1.29	0.54	1.04	0.99–1.1	0.14			
CARDIoGRAMplusC4D	0.96	0.90–1.02	0.19	0.93	0.87–1.00	0.07	0.97	0.78–1.21	0.79	1.05	0.98–1.12	0.15			
UKBB	1.09	0.97–1.24	0.16	1.06	0.91–1.23	0.45	1.03	0.70–1.51	0.89	1.00	0.90–1.11	1.00			
UKBB	1.04	0.96–1.13	0.35	0.98	0.89–1.08	0.74	0.96	0.75–1.23	0.77	0.95	0.88–1.01	0.11			
UKBB	0.95	0.77–1.18	0.64	0.79	0.61–1.03	0.08	1.35	0.70–2.60	0.37	1.04	0.87–1.25	0.67			
UKBB	0.91	0.67–1.25	0.57	1.01	0.70–1.46	0.94	1.07	0.42–2.74	0.89	0.98	0.75–1.27	0.87			
UKBB	0.78	0.57–1.08	0.13	0.92	0.64–1.35	0.68	1.5	0.58–3.88	0.41	1.10	0.85–1.43	0.46			
FinnGen	1.15	0.81–1.64	0.42	0.94	0.64–1.39	0.76	1.78	0.67–4.72	0.25	1.04	0.81–1.32	0.78			
UKBB	1.15	0.86–1.56	0.34	1.19	0.83–1.70	0.35	2.01	0.78–5.18	0.15	0.82	0.63–1.07	0.14			
FinnGen	1.45	0.99–2.13	0.05	1.20	0.79–1.83	0.40	0.47	0.16–1.36	0.16	0.87	0.67–1.14	0.32			
UKBB	0.89	0.75–1.06	0.20	0.91	0.74–1.13	0.40	1.23	0.72–2.10	0.45	1.02	0.88–1.18	0.83			

CARDIoGRAMplusC4D indicates Coronary Artery Disease Genome-wide Replication and Meta-analysis; FGA, fibrinogen alpha chain; FGB, fibrinogen beta chain; FII, fibrinogen beta chain; OR, odds ratio; and UKBB, UK Biobank.

statistical power (eg, larger number of hemorrhagic stroke cases) or other study designs.

Repurposing anticoagulant drugs for atherosclerotic CVD has been proposed in many large trials, albeit with inconclusive findings.^{32,33} Specifically, effects of anticoagulants targeting factors II and X, such as dabigatran, rivaroxaban, apixaban, and edoxaban, on cardioembolic stroke have been identified. Our findings for factor X are compatible with the effects of previous clinical trials on the prevention of ischemic stroke but not with those on VTE,³⁴ possibly attributable to pleiotropic effects of the genetic variants we employed. The F10 locus is located near the protein Z-dependent protease inhibitor gene, which shows a strong and independent association with ischemic stroke.³⁵ The discrepancy may also be related by our application of genetic proxies for coagulation factors that were identified in Eastern Asian ancestry populations to CVD outcomes in European-ancestry populations. Effects of anti-factor XI drugs on prevention of venous thrombosis have been studied in late-stage trials.³⁶ Given their potential protective effect on cardioembolic stroke highlighted in previous^{29,31} MR studies as well as in our present work, whether such drugs can be used for cardioembolic stroke prevention may also warrant investigation in a clinical trial setting. In addition, and consistent with previous investigation, we also found evidence to support that factor VII may represent a therapeutic target for ischemic stroke.³⁷ Phenome-wide association studies on genetically proxied inhibition of coagulation factors represents a further approach to investigate the broad repurposing potential and adverse effect profile of anticoagulant drug classes.³⁸ Current evidence on the role of fibrinogen is conflicting, with previous studies identifying relationships with both increased and decreased risk of venous thrombosis.^{39,40} A recent MR study revealed that elevated fibrinogen gamma levels (based on 16 genetic instruments) and total fibrinogen levels (based on 75 genetic instruments) were associated with a decreased risk for thrombosis.⁴⁰ Our findings, however, did not support these associations. The reasons underlying this discrepancy are unclear and may be related to our scaling of variant effects based on their relation to aPTT, while the previous study considered circulating fibrinogen levels.⁴⁰ We note that coagulation factors may alter the risk of thrombosis by mechanisms that do not affect the aPTT, such as factor XIII activation and related fibrinolysis.⁴¹ In addition, we noticed that differences in the effects of 3 chains of fibrinogen on VTE. The fibrin clot is stabilized by activated factor XIII, which crosslinks gamma-gamma and gamma-alpha chains within the network.⁴² This crosslinking may explain a greater effect for variants at FGA and FGG as compared with FGB.

There are several strengths and limitations of the present study. The major merit is the MR design that reduced the bias introduced by unobserved confounding and reverse causation, and therefore strengthened the causal inference in the associations of 9 coagulation factors with CVD. In addition, associations were concordant in 2 independent data sources, which improved the robustness of our findings. We indirectly measured the effects of genetically proxied inhibition of coagulation factors through the association of genetic variants with either aPTT or PT, which limited the comparability of the magnitude of the associations of different coagulation factors with the outcomes. Future studies can adopt an alternative approach to identify variants by their relation to coagulation factor levels. As mentioned above, it may also be that the coagulation factors are exerting effects unrelated to aPTT or PT, which we are unable to measure. Another limitation is that association estimates using robust MR methods were not feasible because of a limited number of SNPs identified for each coagulation factor. Although we cannot rule out that our results might have been affected by potential pleiotropic effects, most incorporated variants were not strongly associated with established risk factors for VTE, stroke, or other CVDs. However, one of the SNPs for factor II and both SNPs for factor XII were associated with height, which is inversely associated with coronary artery disease, ischemic stroke, and peripheral artery disease and positively associated with VTE and atrial fibrillation.⁴³ Thus, the association between genetically proxied inhibition of factor XII and coronary artery disease may be driven by pleiotropic effects related to height. Interestingly, some of the other associations may also be informative of potential adverse effects, such as related to bone mineral density and fracture risk, for example.⁴⁴ Another limitation was that the negative findings might be attributed by lack of sufficient statistical power to detect an effect. However, it is impossible to estimate power in the present MR, as the unit of the effect of used SNPs for anticoagulation factors was not in SD units and the information on SD was unknown in the genome-wide association studies we used. In general, there are concerns about performing post hoc power calculations (ie, after the analysis plan is fixed). The 95% CI for the estimates provides a useful indication of the plausible magnitude of causal effect based on the data available, and hence the extent to which findings are underpowered. Studies with large sample size are warranted to verify the null associations.

CONCLUSIONS

The present MR study supports the efficacy of anticoagulants targeting fibrinogen, factor II, and factor XI in

treating venous thromboembolism and revealed potential applications of inhibition of fibrinogen and factor XI for lowering risk of ischemic stroke, particularly cardioembolic stroke. We also noticed possible protective associations of genetically proxied inhibition of factors V, VII, and X with risk of ischemic stroke, which warrant further study. There was no significant evidence supporting effects on risk of other cardiovascular outcomes related to the use of anticoagulants. However, increased bleeding risk accompanied by these anticoagulants needs to be carefully assessed in further studies.

ARTICLE INFORMATION

Received October 6, 2020; accepted February 15, 2021.

Affiliations

From the Unit of Cardiovascular and Nutritional Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden (S.Y., S.C.L.); Department of Public Health and Primary Care (S.B.) and MRC Biostatistics Unit (S.B.), University of Cambridge, United Kingdom; Centre for Haematology, Imperial College London, United Kingdom (M.L.); British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, United Kingdom (A.M.M.); National Institute for Health Research Cambridge Biomedical Research Centre, University of Cambridge and Cambridge University Hospitals, Cambridge, United Kingdom (A.M.M.); Institute for Stroke and Dementia Research, University Hospital, LMU Munich, Germany (M.D.); Munich Cluster for Systems Neurology (SyNergy), Munich, Germany (M.D.); German Centre for Neurodegenerative Diseases (DZNE, Munich), Munich, Germany (M.D.); Department of Biostatistics and Epidemiology, School of Public Health, Imperial College London, United Kingdom (D.G.); Clinical Pharmacology and Therapeutics Section, Institute of Medical and Biomedical Education and Institute for Infection and Immunity, St George's, University of London, United Kingdom (D.G.); Clinical Pharmacology Group, Pharmacy and Medicines Directorate, St George's University Hospitals NHS Foundation Trust, London, United Kingdom (D.G.); Centre for Pharmacology & Therapeutics, Department of Medicine, Hammersmith Campus, Imperial College London, United Kingdom (D.G.); Novo Nordisk Research Centre Oxford, Oxford, United Kingdom (D.G.); and Unit of Medical Epidemiology, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden (S.C.L.).

Acknowledgments

Analyses of UK Biobank data were conducted under Application Number 29202. Summary-level data for activated partial thromboplastin time and prothrombin time were derived from BioBank Japan. Summary-level data for cardiovascular outcomes were obtained from the FinnGen, CARDIoGRAMplusC4D, and MEGASTROKE consortia. The authors thank all investigators for their efforts and sharing data. The MEGASTROKE project received funding from sources specified at <http://www.megastroke.org/acknowledgments.html>. The author list of MEGASTROKE is listed in <https://www.megastroke.org/authors.html>.

Sources of Funding

Funding for this study came from the Karolinska Institutet's Research Foundation Grants (Grant number 2020-01842), the Swedish Research Council (Vetenskapsrådet; grant no. 2019-00977), the Swedish Research Council for Health, Working Life and Welfare (Forte; grant no. 2018-00123), the Swedish Heart-Lung Foundation (Hjärt-Lungfonden; grant no. 20190247), and the National Institute for Health Research (Cambridge Biomedical Research Centre at the Cambridge University Hospitals National Health Service Foundation Trust). Dipender Gill is supported by the British Heart Foundation Centre of Research Excellence (RE/18/4/34215) at Imperial College London and a National Institute for Health Research Clinical Lectureship at St. George's, University of London (CL-2020-16-001). Amy M. Mason is supported by EC-Innovative Medicines Initiative (BigData@Heart). Stephen Burgess is supported by a Sir Henry Dale Fellowship jointly funded

by the Wellcome Trust and the Royal Society (grant no. 204623/Z/16/Z). Martin Dichgans is supported by the German Research Foundation (DFG) as part of the Munich Cluster for Systems Neurology (EXC 2145 SyNergy). This research was funded in part by the Wellcome Trust. For the purpose of open access, the author has applied a CC-BY public copyright licence to any Author Accepted Manuscript version arising from this submission.

Disclosures

Dr Gill is employed part-time by Novo Nordisk, outside of the submitted work. The remaining authors have no disclosures to report.

Supplementary Material

Tables S1-S5

Figure S1

REFERENCES

- Prandoni P, Lensing AW, Piccoli A, Bernardi E, Simioni P, Girolami B, Marchiori A, Sabbion P, Prins MH, Noventa F, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. *Blood*. 2002;100:3484–3488. DOI: 10.1182/blood-2002-01-0108.
- Dentali F, Douketis JD, Gianni M, Lim W, Crowther MA. Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients. *Ann Intern Med*. 2007;146:278–288. DOI: 10.7326/0003-4819-146-4-200702200-00007.
- Chan KE, Edelman ER, Wenger JB, Thadhani RI, Maddux FW. Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis. *Circulation*. 2015;131:972–979. DOI: 10.1161/CIRCULATIONAHA.114.014113.
- Vinogradova Y, Coupland C, Hill T, Hippisley-Cox J. Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care. *BMJ*. 2018;366:k2505. DOI: 10.1136/bmj.k2505.
- Schurgers LJ, Aebert H, Vermeer C, Bültmann B, Janzen J. Oral anticoagulant treatment: friend or foe in cardiovascular disease? *Blood*. 2004;104:3231–3232. DOI: 10.1182/blood-2004-04-1277.
- López-López JA, Sterne JAC, Thom HHZ, Higgins JPT, Hingorani AD, Okoli GN, Davies PA, Bodalia PN, Bryden PA, Welton NJ, et al. Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis. *BMJ*. 2017;359:j5058. DOI: 10.1136/bmj.j5058.
- Bikdeli B, Gupta A, Mody P, Lampropoulos JF, Dharmarajan K. Most important outcomes research papers on anticoagulation for cardiovascular disease. *Circ Cardiovasc Qual Outcomes*. 2012;5:e65–e74. DOI: 10.1161/CIRCOUTCOMES.112.968701.
- Sharma M, Cornelius VR, Patel JP, Davies JG, Molokhia M. Efficacy and harms of direct oral anticoagulants in the elderly for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism: systematic review and meta-analysis. *Circulation*. 2015;132:194–204. DOI: 10.1161/CIRCULATIONAHA.114.013267.
- Burgess S, Thompson SG. *Mendelian Randomization: Methods for Using Genetic Variants in Causal Estimation*. London: CRC Press; 2015.
- Smith GD, Ebrahim S. 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? *Int J Epidemiol*. 2003;32:1–22. DOI: 10.1093/ije/dyg070.
- Hoffman M, Monroe DM III. A cell-based model of hemostasis. *Thromb Haemost*. 2001;85(6):958–965. DOI: 10.1055/s-0037-1615947.
- Kanai M, Akiyama M, Takahashi A, Matoba N, Momozawa Y, Ikeda M, Iwata N, Ikegawa S, Hirata M, Matsuda K, et al. Genetic analysis of quantitative traits in the Japanese population links cell types to complex human diseases. *Nat Genet*. 2018;50:390–400. DOI: 10.1038/s41588-018-0047-6.
- Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, Downey P, Elliott P, Green J, Landray M, et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. *PLoS Medicine*. 2015;12:e1001779. DOI: 10.1371/journal.pmed.1001779.
- The FinnGen Consortium. FinnGen documentation of r4 release. 2020. Available from <https://finngen.gitbook.io/documentation/>. Accessed 15 December 2020.

15. Malik R, Chauhan G, Traylor M, Sargurupremraj M, Okada Y, Mishra A, Rutten-Jacobs L, Giese A-K, van der Laan SW, Gretarsdottir S, et al. Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes. *Nat Genet.* 2018;50:524–537. DOI: 10.1038/s41588-018-0058-3.
16. Nikpay M, Goel A, Won HH, Hall LM, Willenborg C, Kanoni S, Saleheen D, Kyriakou T, Nelson CP, Hopewell JC, et al. A comprehensive 1,000 Genomes-based genome-wide association meta-analysis of coronary artery disease. *Nat Genet.* 2015;47:1121–1130. DOI: 10.1038/ng.3396.
17. Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, Laurin C, Burgess S, Bowden J, Langdon R, et al. The MR-base platform supports systematic causal inference across the human phenome. *eLife.* 2018;7:e34408. DOI: 10.7554/eLife.34408.
18. Burgess S, Scott RA, Timpson NJ, Davey Smith G, Thompson SG. Using published data in mendelian randomization: a blueprint for efficient identification of causal risk factors. *Eur J Epidemiol.* 2015;30:543–552. DOI: 10.1007/s10654-015-0011-z.
19. Spiller W, Davies NM, Palmer TM. Software application profile: mrrobust—a tool for performing two-sample summary mendelian randomization analyses. *Int J Epidemiol.* 2019;48:684–690. DOI: 10.1093/ije/dyy195.
20. Yavorska OO, Burgess S. Mendelian randomization: an R package for performing mendelian randomization analyses using summarized data. *Int J Epidemiol.* 2017;46:1734–1739. DOI: 10.1093/ije/dyx034.
21. Kamat MA, Blackshaw JA, Young R, Surendran P, Burgess S, Danesh J, Butterworth AS, Staley JR. PhenoScanner V2: an expanded tool for searching human genotype-phenotype associations. *Bioinformatics.* 2019;35(22):4851–4853. DOI: 10.1093/bioinformatics/btz469.
22. Yin OQP, Antman EM, Braunwald E, Mercuri MF, Miller R, Morrow D, Ruff CT, Truitt K, Weitz JI, Giugliano RP. Linking endogenous factor Xa activity, a biologically relevant pharmacodynamic marker, to edoxaban plasma concentrations and clinical outcomes in the engage AF-TIMI 48 trial. *Circulation.* 2018;138:1963–1973. DOI: 10.1161/CIRCULATIONAHA.118.033933.
23. Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP, Mack MJ, Blatchford J, Devenny K, Friedman J, Guiver K, et al. Dabigatran versus warfarin in patients with mechanical heart valves. *N Engl J Med.* 2013;369:1206–1214. DOI: 10.1056/NEJMoa1300615.
24. Kamikubo Y, Miyamoto S, Iwasa A, Ishii M, Okajima K. Purification and characterization of factor VII inhibitor found in a patient with life threatening bleeding. *Thromb Haemost.* 2000;83:60–64. DOI: 10.1055/s-0037-1613758.
25. Nossent AY, Eikenboom JC, Bertina RM. Plasma coagulation factor levels in venous thrombosis. *Semin Hematol.* 2007;44:77–84. DOI: 10.1053/j.seminhematol.2007.01.006.
26. Kuipers S, Cannegieter SC, Doggen CJ, Rosendaal FR. Effect of elevated levels of coagulation factors on the risk of venous thrombosis in long-distance travelers. *Blood.* 2009;113:2064–2069. DOI: 10.1182/blood-2008-06-160135.
27. Girolami A, Ferrari S, Cosi E, Randi ML. Heterozygous FXII deficiency is not associated with an increased incidence of thrombotic events: results of a long term study. *Blood Cells Mol Dis.* 2019;77:8–11. DOI: 10.1016/j.bcmd.2019.03.001.
28. van Walraven C, Hart RG, Singer DE, Laupacis A, Connolly S, Petersen P, Koudstaal PJ, Chang Y, Hellemons B. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. *JAMA.* 2002;288:2441–2448. DOI: 10.1001/jama.288.19.2441.
29. Gill D, Georgakis MK, Laffan M, Sabater-Lleal M, Malik R, Tzoulaki I, Veltkamp R, Dehghan A. Genetically determined FXI (factor XI) levels and risk of stroke. *Stroke.* 2018;49:2761–2763. DOI: 10.1161/STROKEAHA.118.022792.
30. Georgi B, Mielke J, Chaffin M, Khera AV, Gelis L, Mundl H, van Giezen J, Ellinor P, Kathiresan S, Ziegelbauer K, et al. Leveraging human genetics to estimate clinical risk reductions achievable by inhibiting factor XI. *Stroke.* 2019;50:3004–3012. DOI: 10.1161/STROKEAHA.119.026545.
31. Harshfield EL, Sims MC, Traylor M, Ouwehand WH, Markus HS. The role of haematological traits in risk of ischaemic stroke and its subtypes. *Brain.* 2020;143:210–221. DOI: 10.1093/brain/awz362.
32. Bonaca MP, Bauersachs RM, Anand SS, Debus ES, Nehler MR, Patel MR, Fanelli F, Capell WH, Diao L, Jaeger N, et al. Rivaroxaban in peripheral artery disease after revascularization. *N Engl J Med.* 2020;382:1994–2004. DOI: 10.1056/NEJMoa2000052.
33. Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, Diaz R, Alings M, Lonn EM, Anand SS, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. *N Engl J Med.* 2017;377:1319–1330. DOI: 10.1056/NEJMoa1709118.
34. Gill D, Burgess S. Use of a genetic variant related to circulating factor Xa levels to proxy the effect of factor XA inhibition on cardiovascular outcomes. *Circ Genom Precis Med.* 2020;13(5):551–553. Epub ahead of print. DOI: 10.1161/CIRCGEN.120.003061.
35. McQuillan AM, Eikelboom JW, Hankey GJ, Baker R, Thom J, Staton J, Yi Q, Cole V. Protein Z in ischemic stroke and its etiologic subtypes. *Stroke.* 2003;34:2415–2419. DOI: 10.1161/01.STR.0000092124.52084.4B.
36. Büller HR, Bethune C, Bhanot S, Gailani D, Monia BP, Raskob GE, Segers A, Verhamme P, Weitz JI. Factor XI antisense oligonucleotide for prevention of venous thrombosis. *N Engl J Med.* 2015;372:232–240. DOI: 10.1056/NEJMoa1405760.
37. de Vries PS, Sabater-Lleal M, Huffman JE, Marten J, Song CI, Pankratz N, Bartz TM, de Haan HG, Delgado GE, Eicher JD, et al. A genome-wide association study identifies new loci for factor VII and implicates factor VII in ischemic stroke etiology. *Blood.* 2019;133:967–977. DOI: 10.1182/blood-2018-05-849240.
38. Diogo D, Tian C, Franklin CS, Alanne-Kinnunen M, March M, Spencer CCA, Vangjeli C, Weale ME, Mattsson H, Kilpeläinen E, et al. Phenome-wide association studies across large population cohorts support drug target validation. *Nat Commun.* 2018;9:4285. DOI: 10.1038/s41467-018-06540-3.
39. Uitte de Willige S, de Visser MC, Houwing-Duistermaat JJ, Rosendaal FR, Vos HL, Bertina RM. Genetic variation in the fibrinogen gamma gene increases the risk for deep venous thrombosis by reducing plasma fibrinogen gamma' levels. *Blood.* 2005;106:4176–4183. DOI: 10.1182/blood-2005-05-2180.
40. Maners J, Gill D, Pankratz N, Laffan MA, Wolberg AS, de Maat MPM, Ligthart S, Tang W, Ward-Caviness CK, Fornage M, et al. A Mendelian randomization of γ' and total fibrinogen levels on venous thromboembolism and ischemic stroke. *Blood.* 2020;136(26):3062–3069. DOI: 10.1182/blood.2019004781.
41. Standeven KF, Grant PJ, Carter AM, Scheiner T, Weisel JW, Ariens RA. Functional analysis of the fibrinogen alpha thr312ala polymorphism: effects on fibrin structure and function. *Circulation.* 2003;107:2326–2330. DOI: 10.1161/01.CIR.0000066690.89407.CE.
42. Aleman MM, Walton BL, Byrnes JR, Wolberg AS. Fibrinogen and red blood cells in venous thrombosis. *Thromb Res.* 2014;133:S38–S40. DOI: 10.1016/j.thromres.2014.03.017.
43. Lai FY, Nath M, Hamby SE, Thompson JR, Nelson CP, Samani NJ. Adult height and risk of 50 diseases: a combined epidemiological and genetic analysis. *BMC Med.* 2018;16:187. DOI: 10.1186/s12916-018-1175-7.
44. Caraballo PJ, Heit JA, Atkinson EJ, Silverstein MD, O'Fallon WM, Castro MR, Melton LJ III. Long-term use of oral anticoagulants and the risk of fracture. *Arch Intern Med.* 1999;159:1750–1756. DOI: 10.1001/archinte.159.15.1750.

Supplemental Material

Table S1. Detailed information on genetic instruments for coagulation factors.

Factor	Name	Indication	rsID	NEA	EA	EAF	Beta	SE	<i>p</i>
FI	Fibrinogen alpha	aPTT	rs6050	C	T	0.475	0.055	0.007	4.8E-14
FI	Fibrinogen beta	aPTT	rs2059503	A	T	0.128	0.065	0.011	3.1E-09
FI	Fibrinogen gamma	aPTT	rs2066861	T	C	0.491	0.059	0.007	7.3E-16
FII	Prothrombin	PT	rs2070850	T	C	0.551	0.040	0.007	1.5E-09
FV	Proaccelerin or labile factor	PT	rs9332678	T	A	0.596	0.079	0.006	1.3E-40
FV	Proaccelerin or labile factor	PT	rs6013	G	T	0.085	0.209	0.011	1.9E-87
FV	Proaccelerin or labile factor	PT	rs2239853	T	C	0.843	0.045	0.008	3.8E-08
FVII	Proconvertin or stable factor	PT	rs2774033	G	A	0.061	0.450	0.014	1.0E-200
FX	Stuart-Prower factor	PT	rs474810	T	C	0.017	0.394	0.024	1.6E-60
FXI	Plasma thromboplastin antecedent	aPTT	rs56810541	T	A	0.312	0.093	0.008	2.4E-28
FXII	Hageman factor	aPTT	rs4976649	A	G	0.247	0.338	0.010	1.0E-200
aPPT	aPPT	aPTT	rs6013	T	A	0.135	0.088	0.011	5.67E-16
aPPT	aPPT	aPTT	rs754549	G	T	0.085	0.172	0.013	4.33E-39
aPPT	aPPT	aPTT	rs5030081	C	T	0.399	0.059	0.008	3.92E-15
aPPT	aPPT	aPTT	rs1648717	A	G	0.722	0.121	0.008	3.97E-49
aPPT	aPPT	aPTT	rs149893292	A	G	0.505	0.059	0.007	4.31E-16
aPPT	aPPT	aPTT	rs12644950	G	A	0.290	0.072	0.008	1.22E-18
aPPT	aPPT	aPTT	rs56810541	T	A	0.688	0.093	0.008	2.40E-28
aPPT	aPPT	aPTT	rs4976649	G	A	0.175	0.068	0.010	6.20E-12
aPPT	aPPT	aPTT	rs55730132	G	C	0.690	0.225	0.008	4.18E-176
aPPT	aPPT	aPTT	rs7447593	A	G	0.753	0.338	0.010	1.00E-200
aPPT	aPPT	aPTT	rs28696310	A	G	0.337	0.052	0.008	8.66E-11
aPPT	aPPT	aPTT	rs687289	A	G	0.739	0.080	0.009	2.35E-18
aPPT	aPPT	aPTT	rs4962113	A	G	0.726	0.079	0.008	5.77E-21
aPPT	aPPT	aPTT	rs7870707	T	C	0.376	0.080	0.008	2.82E-26
aPPT	aPPT	aPTT	rs9411466	A	G	0.547	0.127	0.007	8.81E-68
aPPT	aPPT	aPTT	rs10793956	A	C	0.326	0.045	0.008	2.77E-08

aPPT	aPPT	aPTT	rs7895470	G	C	0.242	0.053	0.009	2.51E-09
aPPT	aPPT	aPTT	rs7962629	G	A	0.925	0.083	0.014	1.39E-09
aPPT	aPPT	aPTT	rs1801690	C	G	0.104	0.086	0.012	4.68E-13
PT	PT	PT	rs7521392	G	A	0.410	0.038	0.006	1.22E-10
PT	PT	PT	rs1208134	T	C	0.071	0.105	0.012	5.59E-20
PT	PT	PT	rs12022009	G	T	0.399	0.082	0.006	1.03E-41
PT	PT	PT	rs6013	G	T	0.085	0.209	0.011	1.85E-87
PT	PT	PT	rs2239853	T	C	0.843	0.045	0.008	3.78E-08
PT	PT	PT	rs1313566	G	A	0.436	0.037	0.006	3.33E-10
PT	PT	PT	rs2066861	T	C	0.509	0.054	0.006	2.04E-20
PT	PT	PT	rs2481942	A	G	0.060	0.090	0.014	2.65E-11
PT	PT	PT	rs927826	T	G	0.276	0.059	0.007	4.37E-19
PT	PT	PT	rs10761723	C	T	0.493	0.041	0.006	4.42E-12
PT	PT	PT	rs2070850	T	C	0.449	0.040	0.007	1.48E-09
PT	PT	PT	rs57799948	C	T	0.121	0.102	0.011	4.43E-22
PT	PT	PT	rs73576876	G	A	0.280	0.060	0.007	1.68E-19
PT	PT	PT	rs2181540	T	C	0.059	0.412	0.013	1.00E-200
PT	PT	PT	rs867186	G	A	0.959	0.150	0.015	5.64E-24

aPTT, indicates activated partial thromboplastin time; EA, effect allele; EAF, effect allele frequency; FGA, fibrinogen alpha-chain; FGB, fibrinogen beta-chain; FGG, fibrinogen gamma-chain; NEA, non-effect allele; PT, prothrombin time; SE, standard error. Beta estimate for each SNP was scaled to one-unit change in aPTT or PT.

Table S2. Definitions for cardiovascular disease outcomes in UK Biobank.

Outcome	Cases	Controls	ICD-9 diagnosis	ICD-10 diagnosis	OPCS procedure	Self-report†
Coronary artery disease	29 278	338 308	410, 411, 412, 414.0, 414.8, 414.9	I21, I22, I23, I24, I25.1, I25.2, I25.5, I25.6, I25.8, I25.9	K40, K41, K42, K43, K44, K45, K46, K49, K50.1, K50.2, K50.4, K75	20002, 20004, 6150
Heart failure	6712	360 874	402.01, 402.11, 402.91, 404.01, 404.11, 404.91, 404.03, 404.13, 404.93, 428	I11.0, I13.0, I13.2, I50		20002
Atrial fibrillation	16 945	350 641	427.3	I48		20002
Aortic valve stenosis	2244	365 342		I35.0, I35.2		20002
Abdominal aortic aneurysm	1094	366 492	441.3, 441.4	I71.3, I71.4	L19.4, L19.5	20002
Intracerebral hemorrhage	1064	366 522	431	I61		20002
Subarachnoid hemorrhage	1084	366 502	430	I60		20002
Ischemic stroke	4602	362 984	434, 436	I63, I64		20002
Venous thromboembolism	15 602	353 489	415.1, 451.1, 452, 453.0, 453.4, 453.9	I26, I80.1, I80.2, I81, I82.0	L90.2	20002, 6152
Peripheral arterial disease	3415	364 171	443.8, 443.9	I73.8, I73.9		20002

ICD, International Classification of Disease; OPCS, Office of Population Censuses and Surveys Classification of Surgical Operations and Procedures.

Follow-up for incident cases was until March 31, 2017 and date of death was recorded until February 14, 2018.

†Numbers refer to data fields used in UK Biobank: 6150/6152 = Health condition diagnosed by doctor (self-reported); 6177 = Medication for health condition (self-reported); 20002 = Non-cancer illness code (self-reported from interview with nurse); 20004 = Surgical operation code (self-reported from interview with nurse).

Table S3. Definitions for cardiovascular disease outcomes in FinnGen consortium.

Outcomes	Cases	Controls	Diagnostical information		
			ICD-10	ICD-9	ICD-8
Intracerebral hemorrhage	1224	163 533	I61	431	431
Subarachnoid hemorrhage	1019	163 508	I60	430	430
Venous thromboembolism	6913	169 986	O882/I80/O871/I26, excluding I800	415/451, excluding 4510	450 451 671 6739

ICD, International Classification of Disease. Information was obtained from the hospital discharge registry and cause of death registry.

Table S4. Definitions for cardiovascular disease outcomes in consortia

Outcomes	Consortium	Cases	Controls	Diagnostical information
Coronary artery disease	CARDIoGRAMplusC4D	60 801	123 504	Case status was defined by an inclusive coronary artery disease diagnosis (for example, myocardial infarction, acute coronary syndrome, chronic stable angina or coronary stenosis of >50%).
Any ischemic stroke	MEGASTROKE	60 341	NA	The stroke cases were defined as rapidly developing signs of focal (or global) disturbance of cerebral function, lasting more than 24 hours or leading to death with no apparent cause other than that of vascular origin. Any ischemic stroke was defined by all stroke cases except for intracerebral hemorrhage. Any ischemic stroke included large artery ischemic stroke, cardioembolic ischemic stroke, and small vessel ischemic stroke according to the Trial of Org 10,172 in Acute Stroke Treatment criteria, and also included ischemic stroke of undefined subtype.
Large artery stroke	MEGASTROKE	6688	146 392	
Small vessel stroke	MEGASTROKE	11 710	192 662	
Cardioembolic stroke	MEGASTROKE	9006	204 570	


NA, not available.

Table S5. Phenotypes associated with used SNPs at genome-wide significance†.

Factor	SNP	EA	Associated phenotype	Beta
F1	rs6050	T	Gamma fibrinogen levels	NA
			Plasma fibrin D dimer levels	NA
			Pulmonary embolism	-0.001
			Blood clot in the leg	-0.003
			Phlebitis and thrombophlebitis	-0.001
			Venous thrombosis	NA
F1	rs2059503	T	Aspartate transaminase	0.020
F1	rs2066861	C	Gamma fibrinogen levels	NA
			Self-reported DVT	-0.003
			Pulmonary embolism	-0.001
			Phlebitis and thrombophlebitis	-0.001
FII	rs2070850	C	High-density lipoprotein cholesterol	-0.053
			Height	-0.016
			Forced vital capacity	-0.020
			Heel bone mineral density	-0.029
			Self-reported hypertension	0.009
FV	rs9332678	A	None	
FV	rs6013	T	None	
FV	rs2239853	C	None	
FVII	rs2774033	A	None	
FX	rs474810	C	Factor VII clotting activity	NA
			Factor X antigen	NA
FXI	rs56810541	A	Self-reported DVT	-0.003
			Self-reported pulmonary embolism	-0.001
			Phlebitis and thrombophlebitis	-0.001
FXI	rs4253421	A	Self-reported pulmonary embolism	-0.003
			Self-reported DVT	-0.004
FXII	rs4976649	G	Height	0.013

†Pleiotropic phenotypes were obtained by a search in <http://www.phenoscanter.medschl.cam.ac.uk/>.
DVT, deep vein thrombosis; EA, effect allele; SNP, single-nucleotide polymorphism.

Figure S1. Genetically predicted aPTT and PT in relation to cardiovascular disease.



Activated partial thromboplastin time, aPTT; CI, confidence interval; CVD, cardiovascular disease; OR, odds ratio; prothrombin time, PT.